Cortes Jorge E, Candoni Anna, Clark Richard E, Leber Brian, Montesinos Pau, Vyas Paresh, Zeidan Amer M, Heuser Michael
Division of Hematology and SCT, Georgia Cancer Center, Augusta, GA, USA.
University Hospital of Udine-ASUFC, Udine, Italy.
Leuk Lymphoma. 2020 Dec;61(14):3287-3305. doi: 10.1080/10428194.2020.1817445. Epub 2020 Sep 24.
Glasdegib, in combination with low-dose cytarabine (LDAC), is the first smoothened inhibitor approved for treatment of acute myeloid leukemia. Glasdegib plus LDAC is indicated for patients in whom therapy options are limited, e.g. older patients and those ineligible for intensive chemotherapy due to preexisting comorbidities. This review summarizes the recommendations of a panel of hemato-oncologists regarding the selection of patients best suited for treatment with glasdegib plus LDAC and the management during therapy with this combination. The panel considered the impact of concomitant medications and comorbidities during treatment with glasdegib plus LDAC, and discussed common adverse events (AEs) associated with glasdegib plus LDAC. Management strategies for AEs discussed by the panel included dose modifications, supportive care therapies, and prophylactic treatments. Finally, the panel highlighted the importance of patient communication and education regarding the possible AEs that may occur during treatment.
格拉斯吉布与小剂量阿糖胞苷（LDAC）联合使用，是首个获批用于治疗急性髓系白血病的 smoothened 抑制剂。格拉斯吉布加 LDAC 适用于治疗选择有限的患者，例如老年患者以及因已有合并症而不适合强化化疗的患者。本综述总结了血液肿瘤学家小组关于选择最适合使用格拉斯吉布加 LDAC 治疗的患者以及该联合治疗期间管理的建议。该小组考虑了格拉斯吉布加 LDAC 治疗期间合并用药和合并症的影响，并讨论了与格拉斯吉布加 LDAC 相关的常见不良事件（AE）。该小组讨论的 AE 管理策略包括剂量调整、支持性护理疗法和预防性治疗。最后，该小组强调了就治疗期间可能发生的 AE 与患者沟通和教育的重要性。
